Sign in
Enrolling by invitationNo phase

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

Key facts

Who runs it
Nanjing Medical University
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
People taking part
200 people, planned
Started
1 Apr 2025
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ulinastatin and Thymosin α1
  • Ulinastatin only
Record updated
14 January 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset
  • Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled
  • The patients' age between 18 ~90 years old
  • Agree to participate in the study and sign the informed consent

Who cannot take part

  • Patients allergic to Thymosin α1 or Ulinastatin
  • Patients with mental diseases, drug and alcohol dependence
  • Lactating women and pregnant women
  • Refuse to participate in this study and refuse to sign the informed consent

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha

Read full original descriptionShow less

1 in addition to antiinflammatory treatment may be beneficial. This study was designed to test the hypothesis that the administration of Ulinastatin and Thymosin α1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.

The 2 groups in the trial

  • UT GroupTreatment being tested

    Ulinastatin (100000U TID for 5 days) and Thymosin alpha 1 (1.6 mg q12h for 5 days) immediately after surgery

    Treatment: Ulinastatin and Thymosin α1

  • Control GroupExisting treatment, for comparison

    Ulinastatin (100000U TID for 5 days) immediately after surgery

    Treatment: Ulinastatin only

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06966687, who can take part
Record updated
14 January 2026